Case number 1:23-cv-00101
Novo Nordisk Inc. et al v. Mylan Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jul 3, 2025 | 302 | [SEALED] Letter to the Honorable Colm F. Connolly from Stamatios Stamoulis regarding Responding to Novo Nordisk's Dispute Letter - re 301 Letter,. (Stamoulis, Stamatios) (Entered: 07/03/2025) (0) |
| Jul 3, 2025 | 303 | [SEALED] DECLARATION of Frank W. Rockhold, Ph.D. re 302 Letter by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 07/03/2025) (0) |
| Jul 2, 2025 | 301 | [SEALED] Letter to The Honorable Colm F. Connolly from Brian P. Egan regarding Protective Order dispute - re Oral Order,, Set Hearings,. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Text of Proposed Order)(Egan, Brian) (Entered: 07/02/2025) (0) |
| Jun 27, 2025 | 299 | NOTICE to Take Deposition of Nitin Bhattad on June 30, 2025 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/27/2025) (4) |
| Jun 27, 2025 | 300 | NOTICE to Take Deposition of Pat Vallano on July 10, 2025 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/27/2025) (4) |
| Jun 11, 2025 | 297 | NOTICE OF SERVICE of Plaintiffs Novo Nordisk Inc. and Novo Nordisk A/S's Second Set of Interrogatories to Defendant (Nos. 10-14) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/11/2025) (3) |
| Jun 11, 2025 | 298 | NOTICE OF SERVICE of (1) Defendants Fifth Set of Requests for Production to Plaintiffs (No. 59) and (2) Defendants Third Set of Request for Admission to Plaintiffs (Nos. 10-11) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 06/11/2025) (2) |
| Jun 10, 2025 | 296 | Letter to The Honorable Colm F. Connolly from Travis J. Murray regarding response to Mylan's Notice of Supplemental Authority - re 289 Letter,. (Murray, Travis) (Entered: 06/10/2025) (2) |
| Jun 6, 2025 | 293 | NOTICE to Take Deposition of Dave Mitchell on June 17, 2025 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/06/2025) (4) |
| Jun 6, 2025 | 294 | NOTICE to Take Deposition of Charlotte Karlum Borchert on July 3, 2025 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 06/06/2025) (3) |
| Jun 6, 2025 | 295 | NOTICE OF SERVICE of Defendants Second Set of Requests for Admission to Plaintiffs (Nos. 7-9) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 06/06/2025) (2) |
| Jun 2, 2025 | 292 | NOTICE OF SERVICE of Defendants Fifth Set of Interrogatories to Plaintiffs (No. 18) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 06/02/2025) (2) |
| May 23, 2025 | 291 | NOTICE of Withdrawal of Counsel by Novo Nordisk A/S, Novo Nordisk Inc. (Egan, Brian) (Entered: 05/23/2025) (4) |
| May 16, 2025 | 290 | ANSWER to 284 Answer to Complaint, Counterclaim - by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 05/16/2025) (11) |
| May 9, 2025 | 289 | Letter to the Honorable Colm F. Connolly from Stamatios Stamoulis regarding Enclosing Supplemental Authority - re 160 MOTION for Judgment on the Pleadings Pursuant to FRCP 12(C) Regarding U.S. Patent No. 9,764,003. (Attachments: # 1 Exhibit 1)(Stamoulis, Stamatios) (Entered: 05/09/2025) (0) |
| May 7, 2025 | 287 | MOTION for Pro Hac Vice Appearance of Attorney Rodney Swartz and Emily Iroz Rich - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 05/07/2025) (6) |
| May 7, 2025 | 288 | Pro Hac Vice Fee - Credit Card Payment received for Rodney Swartz and Emily Iroz Rich. ( re 287 MOTION for Pro Hac Vice Appearance of Attorney Rodney Swartz and Emily Iroz Rich )( Payment of $ 100, receipt number ADEDC-4681509).(Stamoulis, Stamatios) (Entered: 05/07/2025) (0) |
| May 5, 2025 | 286 | NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.s Objections and Responses to First Set of Requests for Admissions (Nos. 1-4) filed by Mylan Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 05/05/2025) (2) |
| Apr 25, 2025 | 284 | ANSWER to Complaint Separate Defenses, COUNTERCLAIM to Complaint Asserting U.S. Patent No. 12,214,017 against Mylan Pharmaceuticals Inc. by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 04/25/2025) (26) |
| Apr 25, 2025 | 285 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Mylan Inc., Corporate Parent Viatris Inc. for Mylan Pharmaceuticals Inc. filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 04/25/2025) (2) |
| Apr 24, 2025 | 283 | NOTICE to Take Deposition of Marianne Oelholm Larsen Groenning, Ph.D. on June 11, 2025 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 04/24/2025) (3) |
| Apr 11, 2025 | 282 | NOTICE OF SERVICE of (1) Plaintiffs' Initial Infringement Contentions Regarding Defendant Mylan Pharmaceuticals Inc. For U.S. Patent No. 12,214,017 and (2) Plaintiffs Novo Nordisk Inc. and Novo Nordisk A/S's First Set of Requests for Admission to Defendant Mylan Pharmaceuticals Inc. (Nos. 1-4) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 04/11/2025) (5) |
| Apr 10, 2025 | 280 | STIPULATION and [Proposed] Order Regarding Defendant Mylan Pharmaceuticals Inc.'s Response to Complaint - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 04/10/2025) (2) |
| Apr 10, 2025 | 281 | SO ORDERED, re 280 Stipulation Regarding Defendant Mylan Pharmaceuticals Inc.'s Response to Complaint. The deadline for Mylan to answer, move, or otherwise respond to the '017 Patent Complaint shall be April 25, 2025. Signed by Judge Colm F. Connolly on 4/10/2025. (mws) (Entered: 04/10/2025) (2) |
| Apr 9, 2025 | 278 | Letter to The Honorable Colm F. Connolly from Travis J. Murray regarding claim construction for U.S. Patent No. 12,214,017 and the June 25, 2025 Markman hearing. (Attachments: # 1 Proposed Order)(Murray, Travis) (Entered: 04/09/2025) (0) |
| Apr 9, 2025 | 279 | SO ORDERED, re Proposed Order (Attachment to 278 Letter). The June 25, 2025 Markman Hearing is cancelled. Signed by Judge Colm F. Connolly on 4/9/2025. (mws) (Entered: 04/09/2025) (2) |
| Apr 7, 2025 | 277 | SO ORDERED, re 276 STIPULATION TO EXTEND TIME for Plaintiffs Novo Nordisk Inc. and Novo Nordisk A/S to serve their Opening Claim Construction Brief for U.S. Patent No. 12,214,017 to April 9, 2025, filed by Novo Nordisk A/S, Novo Nordisk Inc. Reset Deadlines for Claim Construction Briefing and Markman Hearing: Claim Construction Opening Brief due by 4/9/2025. Signed by Judge Colm F. Connolly on 4/7/2025. (kmd) (Entered: 04/07/2025) (2) |
| Apr 4, 2025 | 276 | STIPULATION TO EXTEND TIME for Plaintiffs Novo Nordisk Inc. and Novo Nordisk A/S to serve their Opening Claim Construction Brief for U.S. Patent No. 12,214,017 to April 9, 2025 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 04/04/2025) (2) |
| Apr 3, 2025 | 275 | NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Defendant's Fourth Set of Requests for Production to Plaintiffs (Nos. 51-58) and (2) Plaintiffs' Objections and Responses to Defendant's Fourth Set of Interrogatories (Nos. 15-17) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 04/03/2025) (3) |
| Mar 27, 2025 | 274 | NOTICE OF SERVICE of (1) Plaintiffs' Supplemental Objections and Responses to Defendant's First Set of Requests for Admission to Plaintiffs (Nos. 1-6) and (2) Plaintiff's First Supplemental Objections and Responses to Defendant's Interrogatory Nos. 1-3, 7, 9-11, and 14 and Second Supplemental Objections and Responses to Defendant's Interrogatory No. 6 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/27/2025) (5) |
| Mar 21, 2025 | 269 | CLAIM CONSTRUCTION ORDER re 257 Proposed Order. Signed by Judge Colm F. Connolly on 3/21/2025. (mws) (Entered: 03/21/2025) (3) |
| Mar 21, 2025 | 270 | SO ORDERED, re (15 in 1:24-cv-00050-CFC, 255 in 1:23-cv-00101-CFC) Stipulation Dismissing U.S. Patent Nos. 10,888,605 and 11,752,198 Without Prejudice. Signed by Judge Colm F. Connolly on 3/21/2025. Associated Cases: 1:23-cv-00101-CFC, 1:24-cv-00050-CFC (mws) (Entered: 03/21/2025) (3) |
| Mar 21, 2025 | 271 | SO ORDERED, re (256 in 1:23-cv-00101-CFC, 7 in 1:25-cv-00276-CFC) Joint MOTION to Consolidate Cases (Case No. 25-276 into Lead Case 23-101-CFC) filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 3/21/2025. Associated Cases: 1:23-cv-00101-CFC, 1:25-cv-00276-CFC(mws) (Entered: 03/21/2025) (2) |
| Mar 21, 2025 | 272 | CONSOLIDATED CASE SCHEDULE re 256 JOINT Motion and Proposed Order. Signed by Judge Colm F. Connolly on 3/21/2025. (mws) (Entered: 03/21/2025) (4) |
| Mar 21, 2025 | 273 | NOTICE OF SERVICE of (1) Plaintiffs' Initial Responses to Defendant's Initial Invalidity Contentions Regarding U.S. Patent No. 12,214,017, (2) Novo Nordisk's Preliminary Disclosure of Asserted Claims Regarding U.S. Patent No. 12,214,017 and (3) Novo Nordisk's Preliminary Disclosure of Asserted Claims Regarding U.S. Patent No. 12,029,779 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/21/2025) (7) |
| Mar 19, 2025 | 266 | NOTICE to Take Deposition of Lars Endahl, Ph.D. on March 28, 2025 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/19/2025) (3) |
| Mar 19, 2025 | 267 | NOTICE to Take Deposition of Joakim Lundqvist, Ph.D. on March 25, 2025 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/19/2025) (3) |
| Mar 19, 2025 | 268 | NOTICE to Take Deposition of Anders Bjerring Strathe, Ph.D. on March 27, 2025 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/19/2025) (3) |
| Mar 18, 2025 | 265 | SO ORDERED, re 264 Stipulation Regarding Claim Construction of Terms in U.S. Patent No. 12,029,779. Signed by Judge Colm F. Connolly on 3/18/2025. (mws) (Entered: 03/18/2025) (3) |
| Mar 17, 2025 | 264 | STIPULATION and [Proposed] Order Regarding Claim Construction of Terms in U.S. Patent No. 12,029,779 by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 03/17/2025) (3) |
| Mar 16, 2025 | 263 | NOTICE OF SERVICE of Defendants Initial Noninfringement Contentions for U.S. Patent No. 12,214,017 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/16/2025) (2) |
| Mar 13, 2025 | 262 | SO ORDERED, re 259 STIPULATION TO EXTEND TIME to submit the Joint Claim Construction Chart for the '779 Patent to March 17, 2025, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 3/13/2025. (kmd) (Entered: 03/13/2025) (2) |
| Mar 12, 2025 | 259 | STIPULATION TO EXTEND TIME to submit the Joint Claim Construction Chart for the '779 Patent to March 17, 2025 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 03/12/2025) (2) |
| Mar 12, 2025 | 260 | NOTICE to Take Deposition of 30(b)(6) Representative filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/12/2025) (10) |
| Mar 12, 2025 | 261 | NOTICE to Take Deposition of Anne McCaughan on March 14, 2025 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/12/2025) (3) |
| Mar 10, 2025 | 255 | STIPULATION and [Proposed] Order Dismissing U.S. Patent Nos. 10,888,605 and 11,752,198 Without Prejudice - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 03/10/2025) (3) |
| Mar 10, 2025 | 256 | JOINT Motion and Proposed Order to Consolidate Case 25-276 into Lead Case 23-101-CFC - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) Modified on 3/11/2025 (nms). (Entered: 03/10/2025) (10) |
| Mar 10, 2025 | 257 | PROPOSED ORDER -- [Proposed] Claim Construction Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 03/10/2025) (3) |
| Mar 10, 2025 | 258 | Letter to The Honorable Colm F. Connolly from Travis J. Murray regarding context and explanation for recent filings - re (257 in 1:23-cv-00101-CFC) Proposed Order, (256 in 1:23-cv-00101-CFC, 7 in 1:25-cv-00276-UNA) Joint MOTION to Consolidate Cases (Case No. 25-276 into Lead Case 23-101-CFC), (15 in 1:24-cv-00050-CFC, 255 in 1:23-cv-00101-CFC) Stipulation. (Murray, Travis) (Entered: 03/10/2025) (2) |
| Mar 6, 2025 | 254 | SO ORDERED, re 253 Stipulation to Extend Claim Construction Deadlines for the '779 Patent, filed by Novo Nordisk A/S, Novo Nordisk Inc. Reset Deadlines for Claim Construction Briefing and Markman Hearing: Claim Construction Opening Brief due by 4/4/2025. Claim Construction Answering Brief due by 4/25/2025. Claim Construction Reply Brief due by 5/16/2025. Claim Construction Surreply Brief due by 5/30/2025. Joint Claim Construction Brief due by 6/4/2025. Signed by Judge Colm F. Connolly on 3/6/2025. (kmd) (Entered: 03/06/2025) (3) |
| Mar 5, 2025 | 253 | STIPULATION and [Proposed] Order to Extend Claim Construction Deadlines for the '779 Patent - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 03/05/2025) (3) |
| Feb 24, 2025 | 252 | NOTICE OF SERVICE of (1) Defendant Mylan Pharmaceuticals Inc.s Proposed Constructions for the Terms from U.S. Patent no. 12,029,779 and (2) Defendants Initial Invalidity Contentions Regarding U.S. Patent No. 12,214,017 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 02/24/2025) (2) |
| Feb 21, 2025 | 251 | NOTICE OF SERVICE of Plaintiffs' Proposed Constructions and Supporting Intrinsic Evidence for U.S. Patent No. 12,029,779 ("the '779 Patent") - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/21/2025) (5) |
| Feb 18, 2025 | 250 | NOTICE OF SERVICE of Defendants Fourth Set of Interrogatories to Plaintiff (Nos. 15-17) and Defendants Fourth Set of Requests for Production to Plaintiffs (Nos. 51-58) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 02/18/2025) (2) |
| Feb 10, 2025 | 248 | ORDER granting 245 Unopposed MOTION Redact Portions of Hearing Transcript . Signed by Judge Colm F. Connolly on 2/10/2025. (mws) (Entered: 02/10/2025) (1) |
| Feb 10, 2025 | 249 | Official Transcript of Scheduling Teleconference held on 12/6/2024 before Judge Colm F. Connolly. Court Reporter/Transcriber Bonnie Archer, Email: bonnie_archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Release of Transcript Restriction set for 5/12/2025. (mws) (Entered: 02/10/2025) (40) |
| Feb 7, 2025 | 246 | NOTICE OF SERVICE of Novo Nordisk's Disclosure of Terms Proposed for Construction for U.S. Patent Nos. 12,029,779 and 12,214,017 - filed by Novo Nordisk Inc., Novo Nordisk A/S.(Murray, Travis) (Entered: 02/07/2025) (5) |
| Feb 7, 2025 | 247 | NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.s Disclosure of Terms Proposed for Construction for U.S. Patent Nos. 12,029,779 and 12,214,017 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 02/07/2025) (2) |
| Feb 5, 2025 | 245 | [SEALED] Unopposed MOTION Redact Portions of Hearing Transcript - filed by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Text of Proposed Order)(Stamoulis, Stamatios) (Entered: 02/05/2025) (0) |
| Jan 8, 2025 | 237 | NOTICE to Take Deposition of Michael Duelund Soerensen on March 10, 2025 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/08/2025) (3) |
| Jan 8, 2025 | 238 | NOTICE to Take Deposition of Maria Kabisch, Ph.D. on March 5, 2025 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/08/2025) (3) |
| Jan 8, 2025 | 239 | NOTICE to Take Deposition of Thomas Kruse Hansen, Ph.D. on March 7, 2025 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/08/2025) (3) |
| Jan 8, 2025 | 240 | NOTICE to Take Deposition of Charlotte Giwercman Carson, M.D., Ph.D. on February 28, 2025 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/08/2025) (3) |
| Jan 8, 2025 | 241 | NOTICE to Take Deposition of Lars Endahl, Ph.D. on February 26, 2025 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/08/2025) (3) |
| Jan 8, 2025 | 242 | NOTICE to Take Deposition of Anders Bjerring Strathe, Ph.D. on March 3, 2025 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/08/2025) (3) |
| Jan 8, 2025 | 243 | NOTICE to Take Deposition of Marianne Oelholm Larsen Groenning, Ph.D. on February 24, 2025 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/08/2025) (3) |
| Jan 8, 2025 | 244 | NOTICE to Take Deposition of Joakim Lundqvist on March 12, 2025 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/08/2025) (3) |
| Dec 30, 2024 | 236 | [SEALED] NOTICE of Redaction Request by Mylan Pharmaceuticals Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Certificate of Service)(Stamoulis, Stamatios) (Entered: 12/30/2024) (0) |
| Dec 18, 2024 | 235 | NOTICE OF SERVICE of (1) Novo Nordisk's Initial Infringement Contentions Regarding Defendant Mylan Pharmaceuticals Inc. for U.S. Patent No. 12,029,779 and (2) Plaintiffs' Initial Responses to Defendant's Initial Invalidity Contentions Regarding U.S. Patent No. 12,029,779 - filed by Novo Nordisk Inc., Novo Nordisk A/S.(Murray, Travis) (Entered: 12/18/2024) (5) |
| Dec 12, 2024 | 234 | REDACTED VERSION of 232 Proposed Order - by Novo Nordisk Inc., Novo Nordisk A/S. (Murray, Travis) (Entered: 12/12/2024) (4) |
| Dec 11, 2024 | 233 | ORDER REVISING SCHEDULING ORDER re 232 Proposed Order. Reset Scheduling Order Deadlines: (A Markman Hearing is set for 6/25/2025 at 9:00AM in Courtroom 4B before Judge Colm F. Connolly. A Final Pretrial Conference is set for 2/12/2026 at 10:00 AM in Courtroom 4B before Judge Colm F. Connolly. Fact Discovery completed by 7/11/2025. Expert Discovery due by 12/22/2025. Proposed Pretrial Order due by 1/22/2026. A five-day Bench Trial is set to begin 3/2/2026 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly). Signed by Judge Colm F. Connolly on 12/11/2024. (mws) (Entered: 12/11/2024) (0) |
| Dec 9, 2024 | 231 | [SEALED] Official Transcript of Scheduling Teleconference held on 12/6/2024 before Judge Colm F. Connolly. Court Reporter/Transcriber Bonnie Archer. Email: bonnie_archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 12/30/2024. Redacted Transcript Deadline set for 1/9/2025. Release of Transcript Restriction set for 3/10/2025. (mws) Modified on 2/10/2025 (mws). (Entered: 12/09/2024) (0) |
| Dec 9, 2024 | 232 | [SEALED] PROPOSED ORDER Revising Scheduling Order -- by Novo Nordisk Inc., Novo Nordisk A/S. (Murray, Travis) (Entered: 12/09/2024) (0) |
| Dec 6, 2024 | 230 | ORDER granting (227 in 23-101, 12 in 24-1013) Joint MOTION and [Proposed] Order to Consolidate Case No. 24-1013-CFC into Lead Case No. 23-101-CFC. These actions are consolidated for all purposes, and all papers shall be filed in C.A. No. 23-101-CFC. The Protective Order (C.A. No. 23-101-CFC, D.I. 40) and ESI Order (C.A. No. 23-101-CFC, D.I. 43) shall govern. The Scheduling Order shall be modified by the Proposed Consolidated Case Schedule and shall govern. Signed by Judge Colm F. Connolly on 12/6/2024. Associated Cases: 1:23-cv-00101-CFC, 1:24-cv-01013-CFC (mws) Modified on 12/6/2024 (mws). (Entered: 12/06/2024) (2) |
| Nov 26, 2024 | 229 | REDACTED VERSION of (228 in 1:23-cv-00101-CFC, 13 in 1:24-cv-01013-CFC) Letter, by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Ex. A)(Murray, Travis) (Entered: 11/26/2024) (0) |
| Nov 22, 2024 | 227 | Joint MOTION and [Proposed] Order to Consolidate Case No. 24-1013-CFC into Lead Case No. 23-101-CFC - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Murray, Travis) (Entered: 11/22/2024) (5) |
| Nov 22, 2024 | 228 | [SEALED] Letter to The Honorable Colm F. Connolly from Travis J. Murray regarding proposed schedules - re (12 in 1:24-cv-01013-CFC, 227 in 1:23-cv-00101-CFC) Joint MOTION and [Proposed] Order to Consolidate Case No. 24-1013-CFC into Lead Case No. 23-101-CFC . (Attachments: # 1 Exhibit A)(Murray, Travis) (Entered: 11/22/2024) (0) |
| Nov 20, 2024 | 225 | SO ORDERED, re 224 Stipulation to Extend Certain Deadlines Pending Consolidated Scheduling Order, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 11/20/2024. (kmd) (Entered: 11/20/2024) (3) |
| Nov 20, 2024 | 226 | Joint STATEMENT -- Joint Submission Regarding Claim Construction for Term 2 of U.S. Patent No. 11,752,198 -- by Novo Nordisk Inc., Novo Nordisk A/S. (Murray, Travis) (Entered: 11/20/2024) (2) |
| Nov 19, 2024 | 224 | STIPULATION to Extend Certain Deadlines Pending Consolidated Scheduling Order - by Novo Nordisk Inc., Novo Nordisk A/S. (Murray, Travis) (Entered: 11/19/2024) (3) |
| Nov 14, 2024 | 223 | Official Transcript of Status Teleconference held on 10-24-24 before Judge Connolly. Court Reporter Stacy Ingram,Email: stacy_ingram@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 12/5/2024. Redacted Transcript Deadline set for 12/16/2024. Release of Transcript Restriction set for 2/12/2025. (Ingram, Stacy) (Entered: 11/14/2024) (7) |
| Nov 8, 2024 | 221 | STIPULATION TO EXTEND TIME for the parties to serve Opening Expert Reports to December 9, 2024 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 11/08/2024) (2) |
| Nov 8, 2024 | 222 | SO ORDERED, re 221 STIPULATION TO EXTEND TIME for the parties to serve Opening Expert Reports to December 9, 2024, filed by Novo Nordisk A/S, Novo Nordisk Inc. Resetting Scheduling Order Deadlines: Opening Expert Reports due by 12/9/2024. Signed by Judge Colm F. Connolly on 11/8/2024. (kmd) (Entered: 11/08/2024) (2) |
| Nov 6, 2024 | 219 | Supplemental CLAIM CONSTRUCTION REPLY BRIEF re 215 Claim Construction Opening Brief filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit 1, # 2 Appendix to Supplemental Reply Brief)(Stamoulis, Stamatios) (Entered: 11/06/2024) (0) |
| Nov 6, 2024 | 220 | Supplemental CLAIM CONSTRUCTION REPLY BRIEF re 215 Claim Construction Opening Brief Regarding U.S. Patent No. 11,752,198 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit M)(Murray, Travis) (Entered: 11/06/2024) (0) |
| Oct 24, 2024 | 218 | SO ORDERED, re 217 Stipulation Regarding Supplemental Claim Construction, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 10/24/2024. (kmd) (Entered: 10/24/2024) (2) |
| Oct 23, 2024 | 215 | Supplemental CLAIM CONSTRUCTION OPENING BRIEF REGARDING U.S. PATENT NO. 11,752,198 filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 10/23/2024) (30) |
| Oct 23, 2024 | 216 | Supplemental CLAIM CONSTRUCTION OPENING BRIEF Regarding U.S. Patent No. 11,752,198 filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L)(Murray, Travis) (Entered: 10/23/2024) (0) |
| Oct 23, 2024 | 217 | STIPULATION and [Proposed] Order Regarding Supplemental Claim Construction - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 10/23/2024) (2) |
| Oct 22, 2024 | 214 | STIPULATION TO EXTEND TIME for: (1) Final Deadline to Supplement the Preliminary Disclosure of Asserted Claims, Preliminary Disclosure of Prior Art, Infringement Contentions, and Invalidity Contentions; and (2) Final Deadline to Supplement Noninfringement Contentions and Responses to Invalidity Contentions to November 19, 2024 and November 26, 2024, respectively - filed by Novo Nordisk Inc.. (Murray, Travis) (Entered: 10/22/2024) (3) |
| Oct 21, 2024 | 213 | ORAL ORDER Setting Teleconference: Counsel for Plaintiffs to coordinate the call and email the dial-in information to chambers. (A Telephonic Status Conference is set for 10/24/2024 at 9:30 a.m. before Judge Colm F. Connolly). Ordered by Judge Colm F. Connolly on 10/21/2024. (mws) (Entered: 10/21/2024) (0) |
| Oct 17, 2024 | 212 | SO ORDERED, re 210 STIPULATION TO EXTEND TIME for the parties to serve Opening Expert Reports to November 8, 2024, filed by Novo Nordisk A/S, Novo Nordisk Inc. Reset Scheduling Order Deadlines: Opening Expert Reports due by 11/8/2024. Signed by Judge Colm F. Connolly on 10/17/2024. (kmd) (Entered: 10/17/2024) (2) |
| Oct 16, 2024 | 211 | SO ORDERED, re 209 Stipulation Regarding Supplemental Claim Construction Briefing, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 10/16/2024. (kmd) (Entered: 10/16/2024) (3) |
| Oct 10, 2024 | 210 | STIPULATION TO EXTEND TIME for the parties to serve Opening Expert Reports to November 8, 2024 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 10/10/2024) (2) |
| Oct 7, 2024 | 209 | STIPULATION and [Proposed] Order Regarding Supplemental Claim Construction Briefing - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 10/07/2024) (3) |
| Sep 30, 2024 | 208 | Official Transcript of Markman Hearing held on 9/24/2024 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: bonnie_archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 10/21/2024. Redacted Transcript Deadline set for 10/31/2024. Release of Transcript Restriction set for 12/30/2024. (mws) (Entered: 09/30/2024) (156) |
| Sep 26, 2024 | 207 | NOTICE to Take Deposition of Anne McCaughan on to be determined filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 09/26/2024) (3) |
| Sep 23, 2024 | 204 | SO ORDERED, re 203 MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices, filed by Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 9/23/2024. (kmd) (Entered: 09/23/2024) (3) |
| Sep 23, 2024 | 205 | SO ORDERED, re 202 MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 9/23/2024. (kmd) (Entered: 09/23/2024) (3) |
| Sep 23, 2024 | 206 | NOTICE of Subsequent Authority in Support of Plaintiffs' Motion for Claim Construction for Term No. 1 of the '198 Patent by Novo Nordisk A/S, Novo Nordisk Inc. re 190 Joint Claim Construction Brief (Murray, Travis) (Entered: 09/23/2024) (20) |
| Sep 19, 2024 | 202 | MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 09/19/2024) (3) |
| Sep 19, 2024 | 203 | MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 09/19/2024) (3) |
| Sep 3, 2024 | 201 | SO ORDERED, re 200 STIPULATION TO EXTEND TIME for certain deadlines to dates as outlined in stipulation, filed by Novo Nordisk A/S, Novo Nordisk Inc. Resetting Scheduling Order Deadlines: Fact Discovery completed by 10/15/2024. Signed by Judge Colm F. Connolly on 9/3/2024. (kmd) (Entered: 09/03/2024) (3) |
| Aug 30, 2024 | 199 | NOTICE OF SERVICE of (1) Novo Nordisk's First Supplemental Initial Disclosures Pursuant to Fed. R. Civ. P. 26(A); and (2) Plaintiffs' Objections and Responses to Defendant's Third Set of Interrogatories (Nos. 12-14) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 08/30/2024) (5) |
| Aug 30, 2024 | 200 | STIPULATION TO EXTEND TIME for certain deadlines to dates as outlined in stipulation - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 08/30/2024) (3) |
| Aug 29, 2024 | 198 | NOTICE OF SERVICE of Defendants Second Supplemental Objections and Responses to Plaintiffs First Set of Interrogatories (No. 2) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 08/29/2024) (2) |
| Aug 16, 2024 | 196 | REDACTED VERSION of 190 Joint Claim Construction Brief by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 08/16/2024) (30) |
| Aug 16, 2024 | 197 | REDACTED VERSION of 191 Appendix, by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 08/16/2024) (30) |
| Aug 14, 2024 | 195 | Letter to The Honorable Colm F. Connolly from Travis J. Murray regarding claim construction dispute. (Murray, Travis) (Entered: 08/14/2024) (2) |
| Aug 13, 2024 | 192 | REDACTED VERSION of 188 Reply Brief by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 08/13/2024) (20) |
| Aug 13, 2024 | 193 | REDACTED VERSION of 189 Declaration by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit L)(Murray, Travis) (Entered: 08/13/2024) (0) |
| Aug 13, 2024 | 194 | REDACTED VERSION of 187 Reply Brief by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 08/13/2024) (17) |
| Aug 9, 2024 | 190 | [SEALED] JOINT CLAIM CONSTRUCTION BRIEF filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 08/09/2024) (0) |
| Aug 9, 2024 | 191 | [SEALED] APPENDIX re 190 Joint Claim Construction Brief by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit 1, # 14 Exhibit 2, # 15 Exhibit 3)(Murray, Travis) (Entered: 08/09/2024) (0) |
| Aug 6, 2024 | 187 | [SEALED] REPLY BRIEF re 160 MOTION for Judgment on the Pleadings Pursuant to FRCP 12(C) Regarding U.S. Patent No. 9,764,003 filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 08/06/2024) (0) |
| Aug 6, 2024 | 188 | [SEALED] REPLY BRIEF re 167 Cross MOTION for Partial Judgment on the Pleadings filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 08/06/2024) (0) |
| Aug 6, 2024 | 189 | [SEALED] DECLARATION re 188 Reply Brief -- Declaration of Philip S. May -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit L)(Egan, Brian) (Entered: 08/06/2024) (0) |
| Jul 31, 2024 | 185 | NOTICE OF SERVICE of Defendants Third Set of Interrogatories to Plaintiffs (Nos. 12-14) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 07/31/2024) (2) |
| Jul 31, 2024 | 186 | NOTICE OF SERVICE of Novo Nordisk's Reply Claim Construction Brief Regarding U.S. Patent No. 11,752,198 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 07/31/2024) (4) |
| Jul 30, 2024 | 184 | REDACTED VERSION of 178 Answering Brief in Opposition by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 07/30/2024) (23) |
| Jul 29, 2024 | 182 | DEFICIENCY NOTICE by the Court issued to Mylan Pharmaceuticals Inc. re 178 Answering Brief in Opposition. Pursuant to the Court's Standing Order Regarding Briefing in All Cases, dated November 10, 2022, "[t]he covers of briefs filed in connection with all motions except for motions in limine included in a pretrial order shall be as follows: i. Opening Brief - Blue; ii. Answering Brief - Red; iii. Reply Brief - Gray." Courtesy copies of D.I. 178 are not in compliance with the Court's standing order. Each individual document should have attached to it a copy of its Notice of Electronic Filing (NEF) or, as an alternative, the docket item number should be listed on the front of each copy. Please resubmit courtesy copies of your brief with the corrected covers. (kmd) (Entered: 07/29/2024) (2) |
| Jul 29, 2024 | 183 | STIPULATION and [Proposed] Order to Extend Claim Construction Deadlines - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 07/29/2024) (2) |
| Jul 24, 2024 | 180 | MOTION for Pro Hac Vice Appearance of Attorney Aileen Huang - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 07/24/2024) (4) |
| Jul 24, 2024 | 181 | Pro Hac Vice Fee - Credit Card Payment received for Aileen Huang. ( re 180 MOTION for Pro Hac Vice Appearance of Attorney Aileen Huang )( Payment of $ 50, receipt number ADEDC-4459483).(Murray, Travis) (Entered: 07/24/2024) (0) |
| Jul 23, 2024 | 177 | SO ORDERED, re 176 STIPULATION TO EXTEND TIME Briefing Dates and Word Count Limits for Pending Motions to Dates and Limits in Stipulation, filed by Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 7/23/2024. (kmd) (Entered: 07/23/2024) (3) |
| Jul 23, 2024 | 178 | [SEALED] ANSWERING BRIEF in Opposition re 167 Cross MOTION for Partial Judgment on the Pleadings filed by Mylan Pharmaceuticals Inc., Viatris Inc..Reply Brief due date per Local Rules is 7/30/2024. (Stamoulis, Stamatios) (Entered: 07/23/2024) (0) |
| Jul 23, 2024 | 179 | DECLARATION re 178 Answering Brief in Opposition of David L. Anstaett by Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Exhibit 3, # 2 Exhibit 4)(Stamoulis, Stamatios) (Entered: 07/23/2024) (0) |
| Jul 22, 2024 | 176 | STIPULATION TO EXTEND TIME Briefing Dates and Word Count Limits for Pending Motions to Dates and Limits in Stipulation - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 07/22/2024) (3) |
| Jul 18, 2024 | 175 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendant's Third Set of Requests for Production to Plaintiffs (Nos. 45-50) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 07/18/2024) (4) |
| Jul 17, 2024 | 173 | REDACTED VERSION of 168 Brief (Combined Opening and Answering), by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 07/17/2024) (30) |
| Jul 17, 2024 | 174 | REDACTED VERSION of 169 Declaration, by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Ex. A, # 2 Ex. B, # 3 Ex. C, # 4 Ex. D, # 5 Ex. E, # 6 Ex. F, # 7 Ex. G, # 8 Ex. H, # 9 Ex. I, # 10 Ex. J, # 11 Ex. K)(Murray, Travis) (Entered: 07/17/2024) (0) |
| Jul 16, 2024 | 171 | STIPULATION TO EXTEND TIME for Plaintiffs to file redacted versions of D.I. 168 and 169 to July 17, 2024 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 07/16/2024) (2) |
| Jul 16, 2024 | 172 | SO ORDERED, re 171 STIPULATION TO EXTEND TIME for Plaintiffs to file redacted versions of D.I. 168 and 169 to July 17, 2024, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 7/16/2024. (kmd) (Entered: 07/16/2024) (2) |
| Jul 10, 2024 | 170 | NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.s Answering Claim Construction Brief Regarding U.S. Patent No. 11,752,198 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 07/10/2024) (2) |
| Jul 9, 2024 | 167 | Cross MOTION for Partial Judgment on the Pleadings - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Proposed Order)(Murray, Travis) (Entered: 07/09/2024) (0) |
| Jul 9, 2024 | 168 | [SEALED] BRIEF (Combined Opening and Answering) re 167 Cross MOTION for Partial Judgment on the Pleadings , 160 MOTION for Judgment on the Pleadings Pursuant to FRCP 12(C) Regarding U.S. Patent No. 9,764,003 filed by Novo Nordisk A/S, Novo Nordisk Inc..Answering Brief/Response due date per Local Rules is 7/23/2024. Reply Brief due date per Local Rules is 7/16/2024. (Murray, Travis) (Entered: 07/09/2024) (0) |
| Jul 9, 2024 | 169 | [SEALED] DECLARATION re 168 Brief (Combined Opening and Answering), by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Ex. A, # 2 Ex. B, # 3 Ex. C, # 4 Ex. D, # 5 Ex. E, # 6 Ex. F, # 7 Ex. G, # 8 Ex. H, # 9 Ex. I, # 10 Ex. J, # 11 Ex. K)(Murray, Travis) (Entered: 07/09/2024) (0) |
| Jun 18, 2024 | 164 | NOTICE OF SERVICE of (1) Defendants Supplemental Objections and Responses to Plaintiffs First Set of Interrogatories (Nos. 1-9), (2) Defendants Third Set of Request for Production to Plaintiffs (Nos. 45-50), and (3) Mylan Pharmaceuticals Inc.s Objections and Responses to Plaintiffs Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 06/18/2024) (2) |
| Jun 18, 2024 | 165 | REDACTED VERSION of 161 Opening Brief in Support, by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 06/18/2024) (28) |
| Jun 18, 2024 | 166 | REDACTED VERSION of 162 Declaration by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 06/18/2024) (30) |
| Jun 17, 2024 | 163 | NOTICE OF SERVICE of Novo Nordisk's Opening Claim Construction Brief Regarding U.S. Patent No. 11,752,198 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/17/2024) (4) |
| Jun 11, 2024 | 160 | MOTION for Judgment on the Pleadings Pursuant to FRCP 12(C) Regarding U.S. Patent No. 9,764,003 - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Certificate of Compliance, # 2 Text of Proposed Order)(Stamoulis, Stamatios) (Entered: 06/11/2024) (0) |
| Jun 11, 2024 | 161 | [SEALED] OPENING BRIEF in Support re 160 MOTION for Judgment on the Pleadings Pursuant to FRCP 12(C) Regarding U.S. Patent No. 9,764,003 filed by Mylan Pharmaceuticals Inc., Viatris Inc..Answering Brief/Response due date per Local Rules is 6/25/2024. (Stamoulis, Stamatios) (Entered: 06/11/2024) (0) |
| Jun 11, 2024 | 162 | [SEALED] DECLARATION re 161 Opening Brief in Support, of Aaron E. Schindler by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 06/11/2024) (0) |
| Jun 6, 2024 | 157 | CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Additional attachment(s) added on 6/6/2024: # 1 Exhibit A 198 patent) (kmd). (Entered: 06/06/2024) (0) |
| Jun 6, 2024 | 158 | MOTION for Claim Construction re 157 Claim Construction Chart - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 06/06/2024) (4) |
| Jun 6, 2024 | 159 | MOTION for Claim Construction re 157 Claim Construction Chart - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 06/06/2024) (2) |
| Jun 5, 2024 | 156 | Joint STIPULATION TO EXTEND TIME to file the Joint Claim Construction Chart to June 6, 2024 - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 06/05/2024) (2) |
| Jun 3, 2024 | 155 | SO ORDERED, re 154 STIPULATION TO EXTEND TIME for the parties to submit a Joint Claim Construction Chart for U.S. Patent No. 11,752,198 to June 5, 2024, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 6/3/2024. (kmd) (Entered: 06/03/2024) (2) |
| May 31, 2024 | 154 | STIPULATION TO EXTEND TIME for the parties to submit a Joint Claim Construction Chart for U.S. Patent No. 11,752,198 to June 5, 2024 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/31/2024) (2) |
| May 30, 2024 | 153 | SO ORDERED, re 152 STIPULATION TO EXTEND TIME for the deadlines pertaining to the Rule 12(c) motion and briefing to various dates, filed by Novo Nordisk A/S, Novo Nordisk Inc. Reset Briefing Schedule: Opening Brief due 6/11/2024. Answering Brief due 7/9/2024. Reply Brief due 7/23/2024. Signed by Judge Colm F. Connolly on 5/30/2024. (kmd) (Entered: 05/30/2024) (2) |
| May 28, 2024 | 151 | SO ORDERED, re 148 Stipulation to Extend Claim Construction Deadlines for the '198 Patent, filed by Novo Nordisk A/S, Novo Nordisk Inc. Set/Reset Deadlines for Claim Construction Briefing and Markman Hearing: Claim Construction Opening Brief due by 6/17/2024. Claim Construction Answering Brief due by 7/10/2024. Claim Construction Reply Brief due by 7/29/2024. Claim Construction Surreply Brief due by 8/5/2024. Joint Claim Construction Brief due by 8/7/2024. (See Order for further details.) Signed by Judge Colm F. Connolly on 5/28/2024. (kmd) (Entered: 05/28/2024) (3) |
| May 28, 2024 | 152 | STIPULATION TO EXTEND TIME for the deadlines pertaining to the Rule 12(c) motion and briefing to various dates - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/28/2024) (2) |
| May 27, 2024 | 149 | MOTION for Pro Hac Vice Appearance of Attorney Aaron E. Schindler - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 05/27/2024) (4) |
| May 27, 2024 | 150 | Pro Hac Vice Fee - Credit Card Payment received for Aaron E. Schindler. ( re 149 MOTION for Pro Hac Vice Appearance of Attorney Aaron E. Schindler )( Payment of $ 50, receipt number ADEDC-4415729).(Stamoulis, Stamatios) (Entered: 05/27/2024) (0) |
| May 24, 2024 | 148 | STIPULATION and [Proposed] Order to Extend Claim Construction Deadlines for the '198 Patent - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/24/2024) (3) |
| May 21, 2024 | 146 | SO ORDERED, re 145 STIPULATION TO EXTEND TIME for deadlines pertaining to the Rule 12(c) motion and briefing (D.I. 133) to See Stipulation, filed by Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 5/21/2024. (kmd) (Entered: 05/21/2024) (2) |
| May 21, 2024 | 147 | NOTICE OF SERVICE of Plaintiffs' Proposed Constructions and Supporting Intrinsic Evidence for U.S. Patent No. 11,752,198 ("the '198 Patent") - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 05/21/2024) (4) |
| May 20, 2024 | 144 | NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.s identification of proposed construction and intrinsic evidence for U.S. Patent No. 11,752,198 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 05/20/2024) (2) |
| May 20, 2024 | 145 | STIPULATION TO EXTEND TIME for deadlines pertaining to the Rule 12(c) motion and briefing (D.I. 133) to See Stipulation - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 05/20/2024) (2) |
| May 16, 2024 | 142 | STIPULATION and [Proposed] Order to Extend Claim Construction Deadlines for the '198 Patent - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/16/2024) (2) |
| May 16, 2024 | 143 | SO ORDERED, re 142 Stipulation to Extend Claim Construction Deadlines for the '198 Patent, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 5/16/2024. (kmd) (Entered: 05/16/2024) (2) |
| May 10, 2024 | 140 | NOTICE OF SERVICE of Plaintiffs' Identification of Claim Terms in U.S. Patent No. 11,752,198 for Construction - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 05/10/2024) (4) |
| May 10, 2024 | 141 | NOTICE OF SERVICE of Redacted Version of Defendants Initial Noninfringement Contentions for U.S. Patent No. 11,752,198 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 05/10/2024) (2) |
| May 9, 2024 | 139 | NOTICE OF SERVICE of identification of claim terms in U.S. Patent No. 11,752,198 for construction filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 05/09/2024) (2) |
| May 6, 2024 | 138 | NOTICE OF SERVICE of (1) Plaintiffs' Initial Infringement Contentions Regarding Defendant Mylan Pharmaceuticals Inc. for U.S. Patent No. 11,752,198 and (2) Plaintiffs' Initial Responses to Defendant's Initial Invalidity Contentions Regarding U.S. Patent No. 11,752,198 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 05/06/2024) (4) |
| May 2, 2024 | 137 | SO ORDERED, re 136 STIPULATION TO EXTEND TIME Regarding Briefing Schedule for Rule 12(c) Motion to Dates in Stipulation, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 5/2/2024. (kmd) (Entered: 05/02/2024) (2) |
| May 1, 2024 | 136 | STIPULATION TO EXTEND TIME Regarding Briefing Schedule for Rule 12(c) Motion to Dates in Stipulation - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 05/01/2024) (2) |
| Apr 19, 2024 | 135 | NOTICE OF SERVICE of (1) Defendants Initial Noninfringement Contentions for U.S. Patent No. 11,752,198 and (2) Defendants Initial Invalidity Contentions Regarding U.S. Patent No. 11,752,198 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 04/19/2024) (2) |
| Apr 16, 2024 | 134 | ANSWER to Complaint /Counterclaims of Defendant Mylan Pharmaceuticals Inc. ("Mylan") (D.I. 9, C.A. No. 24-50-CFC) - by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 04/16/2024) (11) |
| Apr 11, 2024 | 132 | ORDER granting (129) Motion to Consolidate Cases in case 1:23-cv-00101-CFC; granting (12) Motion to Consolidate Cases in case 1:24-cv-00050-CFC. IT IS HEREBY ORDERED that that these actions are consolidated for all purposes, and all papers shall be filed in C.A. No. 23-101-CFC. IT IS FURTHER ORDERED that the Protective Order (C.A. No. 23-101-CFC, D.I. 40) and ESI Order (C.A. No. 23-101- CFC, D.I. 43) shall govern. The Scheduling Order (C.A. No. 23-101-CFC, D.I. 27) shall be modified by the Proposed Consolidated Case Schedule and shall govern. Signed by Judge Colm F. Connolly on 4/10/2024. Associated Cases: 1:23-cv-00101-CFC, 1:24-cv-00050-CFC(nmf) (Entered: 04/11/2024) (2) |
| Apr 11, 2024 | 133 | CONSOLIDATED CASE SCHEDULING ORDER: Fact Discovery completed by 8/30/2024. Expert Discovery due by 1/20/2025. Joint Claim Construction Brief due by 7/25/2024. A Markman Hearing is set for 9/24/2024 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 3/11/2025. A Final Pretrial Conference is set for 4/1/2025 at 03:00 PM in Courtroom 4B before Judge Colm F. Connolly. A Bench Trial is set for 4/21/2025 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 4/10/2024. (nmf) (Entered: 04/11/2024) (5) |
| Apr 8, 2024 | 131 | REDACTED VERSION of 114 Transcript,, by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 04/08/2024) (30) |
| Apr 4, 2024 | 130 | NOTICE OF SERVICE of Novo Nordisk's Preliminary Disclosure of Asserted Claims Regarding U.S. Patent No. 11,752,198 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 04/04/2024) (5) |
| Mar 28, 2024 | 127 | NOTICE of Intent to Request Redaction by Stamatios Stamoulis re 114 Transcript,,. (Stamoulis, Stamatios) (Entered: 03/28/2024) (2) |
| Mar 28, 2024 | 128 | Letter to The Honorable Colm F. Connolly from Brian P. Egan regarding motion to consolidate. (Egan, Brian) (Entered: 03/28/2024) (1) |
| Mar 28, 2024 | 129 | Joint MOTION to Consolidate Cases - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit A)(Egan, Brian) (Entered: 03/28/2024) (0) |
| Mar 25, 2024 | 126 | MEMORANDUM ORDER re: Claim Construction. Signed by Judge Colm F. Connolly on 3/25/2024. (nmf) (Entered: 03/25/2024) (8) |
| Mar 22, 2024 | 124 | STIPULATION TO EXTEND TIME for the parties to submit a revised proposed scheduling order to March 28, 2024 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 03/22/2024) (2) |
| Mar 22, 2024 | 125 | SO ORDERED, re 124 STIPULATION TO EXTEND TIME for the parties to submit a revised proposed scheduling order to March 28, 2024, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 3/22/2024. (kmd) (Entered: 03/22/2024) (2) |
| Mar 18, 2024 | 123 | NOTICE OF SERVICE of Plaintiffs' Supplemental Objections and Responses to Defendant's First Set of Interrogatories (Nos. 6 & 8) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/18/2024) (3) |
| Mar 15, 2024 | 122 | SO ORDERED, re 121 STIPULATION TO EXTEND TIME for the parties to submit a revised proposed scheduling order, pursuant to the Court's March 6, 2024 Minute Entry, to March 22, 2024, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 3/15/2024. (kmd) (Entered: 03/15/2024) (2) |
| Mar 14, 2024 | 120 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendant's Notice of Deposition of Novo Nordisk Inc. and Novo Nordisk A/S Pursuant to Fed. R. Civ. P. 30(b)(6) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/14/2024) (3) |
| Mar 14, 2024 | 121 | STIPULATION TO EXTEND TIME for the parties to submit a revised proposed scheduling order, pursuant to the Court's March 6, 2024 Minute Entry, to March 22, 2024 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 03/14/2024) (2) |
| Mar 12, 2024 | 117 | NOTICE to Take Deposition of Christine Bjrn Jensen on March 20, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/12/2024) (3) |
| Mar 12, 2024 | 118 | NOTICE to Take Deposition of Eva Horn Mller on March 19, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/12/2024) (3) |
| Mar 12, 2024 | 119 | NOTICE to Take Deposition of Dorthe Kot Engelund on March 15, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/12/2024) (3) |
| Mar 8, 2024 | 116 | REDACTED VERSION of 107 Letter, by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1-5)(Stamoulis, Stamatios) (Entered: 03/08/2024) (0) |
| Mar 7, 2024 | 114 | [SEALED] Official Transcript of Discovery and Status Conference held on March 6, 2024 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: Bonnie_Archer@ded.uscourts.gov. Modified on 6/5/2024 (rlr). (Entered: 03/07/2024) (0) |
| Mar 7, 2024 | 115 | REDACTED VERSION of 101 Letter by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Ex. A, # 2 Ex. B, # 3 Ex. C, # 4 Ex. D, # 5 Ex. E, # 6 Ex. F, # 7 Ex. G)(Murray, Travis) (Entered: 03/07/2024) (0) |
| Mar 4, 2024 | 113 | SO ORDERED, re 109 Stipulation Extending Certain Deadlines, filed by Novo Nordisk A/S, Novo Nordisk Inc. Resetting Scheduling Order Deadlines: Fact Discovery completed by 4/5/2024. Signed by Judge Colm F. Connolly on 3/4/2024. (kmd) (Entered: 03/04/2024) (2) |
| Mar 3, 2024 | 112 | Letter to the Honorable Colm F. Connolly from Stamatios Stamoulis regarding March 6, 2024 Status Conference - re 108 Letter. (Stamoulis, Stamatios) (Entered: 03/03/2024) (1) |
| Mar 1, 2024 | 106 | NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Defendant's Second Set of Requests for Production to Plaintiffs (Nos. 38-44), (2) Plaintiffs' Objections and Responses to Defendant's Second Set of Interrogatories (Nos. 9-11) and (3) Plaintiffs' Objections and Responses to Defendant's First Set of Requests for Admission to Plaintiffs (Nos. 1-6) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/01/2024) (3) |
| Mar 1, 2024 | 107 | [SEALED] Letter to the Honorable Colm F. Connolly from Stamatios Stamoulis regarding Responding to Plaintiff's Dispute Letter - re 101 Letter. (Attachments: # 1 Exhibit 1-5)(Stamoulis, Stamatios) (Main Document 107 replaced on 3/4/2024) (nmf, ). (Entered: 03/01/2024) (0) |
| Mar 1, 2024 | 108 | Letter to The Honorable Colm F. Connolly from Travis Murray regarding Scheduling - re 102 Letter. (Murray, Travis) (Entered: 03/01/2024) (2) |
| Mar 1, 2024 | 109 | STIPULATION and [Proposed] Order Extending Certain Deadlines - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 03/01/2024) (2) |
| Mar 1, 2024 | 110 | NOTICE OF SERVICE of Defendants Objections and Responses to Plaintiffs Second Set of Request for Production of Documents and Things (Nos. 110-119) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/01/2024) (2) |
| Mar 1, 2024 | 111 | NOTICE OF SERVICE of Defendants Supplemental Initial Disclosures Under Fed. R. Civ. P. 26(a)(1) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/01/2024) (2) |
| Feb 29, 2024 | 105 | ORDER granting in part and denying in part 103 MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices. The Motion is granted as to David L. Anstaett, Esq. and Shannon M. Bloodworth, Esq. The Motion is denied as to Preston Imperatore, Esq. Signed by Judge Colm F. Connolly on 2/29/2024. (kmd) (Entered: 02/29/2024) (1) |
| Feb 28, 2024 | 101 | [SEALED] Letter to The Honorable Colm F. Connolly from Travis Murray regarding Discovery Dispute. (Attachments: # 1 Ex. A, # 2 Ex. B, # 3 Ex. C, # 4 Ex. D, # 5 Ex. E, # 6 Ex. F, # 7 Ex. G)(Murray, Travis) (Entered: 02/28/2024) (0) |
| Feb 28, 2024 | 102 | Letter to the Honorable Colm F. Connolly from Stamatios Stamoulis regarding Scheduling Issues to be Addressed in Advance of March 6, 2024 Conference - re 101 Letter. (Stamoulis, Stamatios) (Entered: 02/28/2024) (3) |
| Feb 28, 2024 | 103 | MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 02/28/2024) (3) |
| Feb 28, 2024 | 104 | MOTION to Compel Discovery re 101 [SEALED] Letter to The Honorable Colm F. Connolly from Travis Murray regarding Discovery Dispute - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Certification Regarding Typeface Requirements, # 2 D. Del. LR 7.1.1 Certification, # 3 Text of Proposed Order)(Murray, Travis) (Entered: 02/28/2024) (0) |
| Feb 20, 2024 | 97 | NOTICE to Take Deposition of Kuntal Maiti on March 1, 2024 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/20/2024) (3) |
| Feb 20, 2024 | 98 | NOTICE to Take Deposition of Pat Vallano on March 1, 2024 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/20/2024) (3) |
| Feb 20, 2024 | 99 | NOTICE to Take Deposition of Dilip Jayagopal on March 1, 2024 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/20/2024) (3) |
| Feb 20, 2024 | 100 | NOTICE to Take Deposition of Nitin Bhattad on March 1, 2024 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/20/2024) (3) |
| Feb 15, 2024 | 96 | NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendant's First Set of Interrogatories (Nos. 1-8) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/15/2024) (3) |
| Feb 2, 2024 | 95 | REDACTED VERSION of 91 Notice to Take Deposition by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 02/02/2024) (15) |
| Jan 31, 2024 | 92 | NOTICE to Take Deposition of NIKLAS OHRNER on February 27, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/31/2024) (3) |
| Jan 31, 2024 | 93 | NOTICE OF SERVICE of Second Set of Requests for Production of Documents and Things to Defendant Mylan Pharmaceuticals Inc. (Nos. 110119) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 01/31/2024) (3) |
| Jan 31, 2024 | 94 | NOTICE OF SERVICE of (1) Defendants Second Set of Requests for Production to Plaintiffs (Nos. 38-44), (2) Defendants First Set of Requests for Admission to Plaintiffs (Nos. 1-6), and (3) Defendants Second Set of Interrogatories to Plaintiffs (Nos. 9-11) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/31/2024) (2) |
| Jan 30, 2024 | 91 | [SEALED] NOTICE to Take Deposition of Mylan Pharmaceuticals Inc. on February 23, 2024 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 01/30/2024) (0) |
| Jan 26, 2024 | 90 | NOTICE to Take Deposition of 30(b)(6) Corporate Representative filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 01/26/2024) (16) |
| Jan 25, 2024 | 81 | NOTICE to Take Deposition of Andrew Mark Louw on February 22, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3) |
| Jan 25, 2024 | 82 | NOTICE to Take Deposition of Joakim Lundqvist on February 27, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3) |
| Jan 25, 2024 | 83 | NOTICE to Take Deposition of Sren Snitker on February 16, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3) |
| Jan 25, 2024 | 84 | NOTICE to Take Deposition of Michael Duelund Srensen on February 23, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3) |
| Jan 25, 2024 | 85 | NOTICE to Take Deposition of Stephanie DeChiaro on February 20, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3) |
| Jan 25, 2024 | 86 | NOTICE to Take Deposition of Dorthe Kot Engelund on February 26, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3) |
| Jan 25, 2024 | 87 | NOTICE to Take Deposition of Aneil Batra on February 28, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3) |
| Jan 25, 2024 | 88 | NOTICE to Take Deposition of Eva Horn Mller on February 21, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3) |
| Jan 25, 2024 | 89 | NOTICE to Take Deposition of Christine Bjrn Jensen on February 29, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3) |
| Jan 16, 2024 | 80 | NOTICE OF SERVICE of Defendants First Set of Interrogatories to Plaintiffs (Nos. 1-8) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/16/2024) (2) |
| Dec 15, 2023 | 77 | Letter to the Honorable Colm F. Connolly from Stamatios Stamoulis regarding Supplemental Argument re Claim Construction. (Stamoulis, Stamatios) (Entered: 12/15/2023) (2) |
| Dec 15, 2023 | 78 | Letter to The Honorable Colm F. Connolly from Brian P. Egan regarding construction of claim term - re Oral Order,. (Egan, Brian) (Entered: 12/15/2023) (4) |
| Dec 15, 2023 | 79 | PROPOSED ORDER -- Claim Construction -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 12/15/2023) (3) |
| Dec 14, 2023 | 76 | Official Transcript of Markman Hearing held on December 13, 2023 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: Bonnie_Archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/4/2024. Redacted Transcript Deadline set for 1/16/2024. Release of Transcript Restriction set for 3/13/2024. (nmf) (Entered: 12/14/2023) (122) |
| Dec 12, 2023 | 74 | Letter to The Honorable Colm F. Connolly from Travis Murray regarding response to the Court's Oral Order dated December 11, 2023 - re Oral Order,,,,. (Murray, Travis) (Entered: 12/12/2023) (1) |
| Dec 12, 2023 | 75 | Letter to the Honorable Colm F. Connolly from Stamatios Stamoulis regarding Responding to Court's Oral Order on Proposed Constructions. (Stamoulis, Stamatios) (Entered: 12/12/2023) (4) |
| Dec 8, 2023 | 73 | ORDER granting 72 Amended MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices . Signed by Judge Colm F. Connolly on 12/8/2023. (kmd) (Entered: 12/08/2023) (3) |
| Dec 7, 2023 | 72 | Amended MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 12/07/2023) (3) |
| Dec 6, 2023 | 69 | MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 12/06/2023) (3) |
| Dec 6, 2023 | 70 | ORDER granting 69 MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices. Signed by Judge Colm F. Connolly on 12/6/2023. (kmd) (Entered: 12/06/2023) (3) |
| Dec 6, 2023 | 71 | MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 12/06/2023) (3) |
| Nov 29, 2023 | 67 | CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 11/29/2023) (13) |
| Nov 29, 2023 | 68 | Letter to The Honorable Colm F. Connolly from Travis Murray regarding Amended Joint Claim Construction Chart - re 67 Claim Construction Chart. (Murray, Travis) (Entered: 11/29/2023) (2) |
| Nov 20, 2023 | 66 | SO ORDERED, re 65 STIPULATION TO EXTEND TIME to Amend Pleadings to December 22, 2023, filed by Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 11/20/2023. (kmd) (Entered: 11/20/2023) (2) |
| Nov 17, 2023 | 65 | STIPULATION TO EXTEND TIME to Amend Pleadings to December 22, 2023 - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 11/17/2023) (2) |
| Nov 9, 2023 | 63 | JOINT CLAIM CONSTRUCTION BRIEF filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 11/09/2023) (30) |
| Nov 9, 2023 | 64 | APPENDIX re 63 Joint Claim Construction Brief by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Ex A - US Patent No 9764003, # 2 Ex B - US Patent No 10888605, # 3 Ex C - 003 FH_2014-03-19 Specification, # 4 Ex D - 003 FH_2014-12-19 Preliminary Amendment, # 5 Ex E - 003 FH_2016-03-02 Amendment, # 6 Ex F - 003 FH_2016-08-12 Amendment, # 7 Ex G - 003 FH_2016-09-22 Office Action, # 8 Ex H - 003 FH_2017-03-21 Amendment, # 9 Ex I - 003 FH_2017-04-24 Notice of Allowance, # 10 Ex J - 605 FH_2020-01-28 Application and Claims, # 11 Ex K - 605 FH_2020-05-01 Office Action, # 12 Ex L - 605 FH_2020-07-31 Amendment, # 13 Ex M - 605 FH_11-20-2020_Notice of Allowance, # 14 Ex N - Claim Construction Hrg Tr (excerpted) 22-MD-3038 (DI 146), # 15 Ex O - Claim Construction Order 22-MD-3038 (DI 148), # 16 Ex P - Am Heritage Dictionary, # 17 Ex Q - Stedmans Med Dictionary, # 18 Ex R - Wegovy Prescribing Information)(Murray, Travis) (Entered: 11/09/2023) (0) |
| Nov 6, 2023 | 62 | NOTICE OF SERVICE of (1) Defendants Objections and Responses to Plaintiffs First Set of Interrogatories (Nos. 1-9) and (2) Defendants Objections and Responses to Plaintiffs First Set of Requests for Production of Documents and Things (Nos. 1-109) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 11/06/2023) (2) |
| Nov 2, 2023 | 61 | NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.s Sur-Reply Claim Construction Brief filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 11/02/2023) (2) |
| Oct 31, 2023 | 57 | STIPULATION and [Proposed] Order Regarding Compound Patents - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 10/31/2023) (7) |
| Oct 31, 2023 | 58 | SO ORDERED, re 57 Stipulation Regarding Compound Patents, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 10/31/2023. (kmd) (Entered: 10/31/2023) (7) |
| Oct 31, 2023 | 59 | STIPULATION of Dismissal and [Proposed] Order as to Defendant Viatris Inc. - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 10/31/2023) (3) |
| Oct 31, 2023 | 60 | SO ORDERED, re 59 Stipulation of Dismissal as to Defendant Viatris Inc., filed by Novo Nordisk A/S, Novo Nordisk Inc. Party Viatris Inc. terminated. Attorneys Brandon M. White, Bryan D. Beel, and Stamatios Stamoulis terminated. Signed by Judge Colm F. Connolly on 10/31/2023. (kmd) (Entered: 10/31/2023) (3) |
| Oct 30, 2023 | 56 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' First Set of Requests for Production (Nos. 1-37) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 10/30/2023) (3) |
| Oct 12, 2023 | 55 | NOTICE OF SERVICE of Novo Nordisk's Claim Construction Reply Brief filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 10/12/2023) (3) |
| Oct 5, 2023 | 54 | NOTICE OF SERVICE of (1) Plaintifffs Novo Nordisk Inc. and Novo Noridsk A/Ss First Set of Requests for Production of Documents and Things to Defendants (Nos. 1109) and (2) Plaintifffs Novo Nordisk Inc. and Novo Noridsk A/Ss First Set of Interrogatories to Defendants (Nos. 19) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 10/05/2023) (3) |
| Sep 29, 2023 | 53 | MOTION for Pro Hac Vice Appearance of Attorney David L. Anstaett - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 09/29/2023) (4) |
| Sep 28, 2023 | 52 | NOTICE OF SERVICE of Defendants First Set of Requests for Production to Plaintiffs filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 09/28/2023) (2) |
| Sep 21, 2023 | 51 | NOTICE OF SERVICE of Viatris Inc. and Mylan Pharmaceuticals Inc.s Answering Claim Construction Brief filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 09/21/2023) (2) |
| Aug 24, 2023 | 50 | NOTICE OF SERVICE of Novo Nordisk's Opening Claim Construction Brief - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 08/24/2023) (3) |
| Aug 17, 2023 | 49 | NOTICE OF SERVICE of Novo Nordisk's Disclosure of Final Search Terms Pursuant to Section IV of the ESI Order (D.I. 43) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 08/17/2023) (3) |
| Aug 11, 2023 | 48 | NOTICE OF SERVICE of Plaintiffs Novo Nordisk A/S and Novo Nordisk Inc.'s Disclosure of ESI Search Terms Pursuant to Section IV of the ESI Order (D.I. 43; D.I. 46) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 08/11/2023) (3) |
| Aug 10, 2023 | 46 | SO ORDERED, re 45 STIPULATION TO EXTEND TIME for the parties to exchange a list of intended terms to be used to search their ESI (D.I. 43) to August 10, 2023, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 8/10/2023. (kmd) (Entered: 08/10/2023) (2) |
| Aug 10, 2023 | 47 | NOTICE OF SERVICE of Defendants identification of terms Defendants intends to use to search their ESI filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 08/10/2023) (2) |
| Aug 9, 2023 | 45 | STIPULATION TO EXTEND TIME for the parties to exchange a list of intended terms to be used to search their ESI (D.I. 43) to August 10, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 08/09/2023) (2) |
| Aug 8, 2023 | 44 | NOTICE OF SERVICE of (1) Plaintiffs' Initial Infringement Contentions Regarding Defendants Viatris Inc. and Mylan Pharmaceuticals Inc. and (2) Plaintiffs' Initial Responses to Defendants' Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 9,764,003; 10,888,605; and 11,318,191 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 08/08/2023) (4) |
| Aug 3, 2023 | 42 | STIPULATED PROTECTIVE ORDER Pursuant to Federal Rule of Civil Procedure 26(c). Signed by Judge Colm F. Connolly on 8/3/2023. (kmd) (Entered: 08/03/2023) (30) |
| Aug 3, 2023 | 43 | SO ORDERED, re 41 Stipulated Order Regarding the Discovery of Electronically Stored Information, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 8/3/2023. (kmd) (Entered: 08/03/2023) (15) |
| Aug 2, 2023 | 40 | PROPOSED ORDER Protective Order by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 08/02/2023) (30) |
| Aug 2, 2023 | 41 | STIPULATION Stipulated Order Regarding the Discovery of Electronically Stored Information by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 08/02/2023) (15) |
| Jul 31, 2023 | 37 | CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Ex. A - '343 Patent, # 2 Ex. B - '122 Patent, # 3 Ex. C - '003 Patent, # 4 Ex. D - '605 Patent, # 5 Ex. E - '191 Patent)(Egan, Brian) (Entered: 07/31/2023) (0) |
| Jul 31, 2023 | 38 | MOTION for Claim Construction re 37 Claim Construction Chart, - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 07/31/2023) (3) |
| Jul 31, 2023 | 39 | MOTION for Claim Construction - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 07/31/2023) (2) |
| Jul 26, 2023 | 36 | STIPULATION TO EXTEND TIME for Parties to Submit Proposed Protective Order and Proposed ESI Order pursuant to Court's Scheduling Order [D.I. 27] to August 2, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 07/26/2023) (2) |
| Jul 21, 2023 | 34 | NOTICE OF SERVICE of Plaintiffs' Proposed Constructions and Supporting Intrinsic Evidence filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 07/21/2023) (3) |
| Jul 21, 2023 | 35 | NOTICE OF SERVICE of Defendants Identification of Proposed Constructions and Intrinsic Evidence filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 07/21/2023) (2) |
| Jul 19, 2023 | 32 | STIPULATION TO EXTEND TIME to submit a proposed Protective Order and a proposed ESI Order to July 26, 2023 - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 07/19/2023) (2) |
| Jul 19, 2023 | 33 | SO ORDERED, re 32 STIPULATION TO EXTEND TIME to submit a proposed Protective Order and a proposed ESI Order to July 26, 2023, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 7/19/2023. (kmd) (Entered: 07/19/2023) (2) |
| Jul 11, 2023 | 31 | SO ORDERED, re 30 STIPULATION TO EXTEND TIME to Submit Proposed Protective Order to July 19, 2023, filed by Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 7/11/2023. (kmd) (Entered: 07/11/2023) (2) |
| Jul 10, 2023 | 30 | STIPULATION TO EXTEND TIME to Submit Proposed Protective Order to July 19, 2023 - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 07/10/2023) (2) |
| Jun 28, 2023 | 29 | NOTICE OF SERVICE of Plaintiffs' Identification of Inventors Employed by Plaintiffs and/or Represented by Counsel for Plaintiffs - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 06/28/2023) (3) |
| Jun 22, 2023 | 28 | NOTICE OF SERVICE of (1) Defendants Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 9,764,003; 10,888,605; and 11,318,191 and (2) Defendants Initial Noninfringement Contentions filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 06/22/2023) (2) |
| Jun 21, 2023 | 27 | SCHEDULING ORDER: Joinder of Parties due by 11/17/2023. Amended Pleadings due by 11/17/2023. Fact Discovery completed by 3/1/2024. Expert Discovery due by 8/9/2024. Joint Claim Construction Brief due by 11/9/2023. A Markman Hearing is set for 12/13/2023 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 11/20/2024. A Final Pretrial Conference is set for 12/11/2024 at 03:00 PM in Courtroom 4B before Judge Colm F. Connolly. A Bench Trial is set for 12/16/2024 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 6/21/2023. (nmf) (Entered: 06/21/2023) (28) |
| Jun 20, 2023 | 26 | Joint PROPOSED ORDER -- [Proposed] Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Cover Letter to The Honorable Colm F. Connolly)(Egan, Brian) (Entered: 06/20/2023) (Main Document) (28) |
| Jun 20, 2023 | 26 | Joint PROPOSED ORDER -- [Proposed] Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Cover Letter to The Honorable Colm F. Connolly)(Egan, Brian) (Entered: 06/20/2023) (Cover Letter to The Honorable Colm F. Connolly) (1) |
| Jun 8, 2023 | 25 | Official Transcript of In-Person Scheduling Conference held on June 6, 2023 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: Bonnie_Archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 6/29/2023. Redacted Transcript Deadline set for 7/10/2023. Release of Transcript Restriction set for 9/6/2023. (nmf) (Entered: 06/08/2023) (0) |
| Jun 6, 2023 | N/A | SO ORDERED, re 24 MOTION for Pro Hac Vice Appearance of Attorney Shannon M. Bloodworth, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Ordered by Judge Colm F. Connolly on 6/6/2023. (kmd) (Entered: 06/06/2023) (0) |
| Jun 6, 2023 | N/A | Minute Entry for proceedings held before Judge Colm F. Connolly - In-Person Scheduling Conference held on 6/6/2023. (Court Reporter Bonnie Archer.) Counsel to submit a revised proposed scheduling order to the Court on or before June 20, 2023. (nmf) (Entered: 06/06/2023) (0) |
| Jun 5, 2023 | 24 | MOTION for Pro Hac Vice Appearance of Attorney Shannon M. Bloodworth - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 06/05/2023) (4) |
| May 30, 2023 | 23 | MOTION for Pro Hac Vice Appearance of Attorney Philip S. May - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 05/30/2023) (4) |
| May 30, 2023 | N/A | SO ORDERED, re 23 MOTION for Pro Hac Vice Appearance of Attorney Philip S. May, filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 5/30/2023. (kmd) (Entered: 05/30/2023) (0) |
| May 30, 2023 | N/A | Pro Hac Vice Attorney Philip S. May for Novo Nordisk A/S and Novo Nordisk Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (apk) (Entered: 05/30/2023) (0) |
| May 17, 2023 | N/A | Pro Hac Vice Attorney Bryan D. Beel and Brandon M. White for Mylan Pharmaceuticals Inc. and Viatris Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 05/17/2023) (0) |
| May 16, 2023 | N/A | Pro Hac Vice Attorney Emily J. Greb for Mylan Pharmaceuticals Inc., Viatris Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) (Entered: 05/16/2023) (0) |
| May 15, 2023 | 22 | NOTICE OF SERVICE of Novo Nordisk's Preliminary Disclosure of Asserted Claims filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 05/15/2023) (3) |
| May 10, 2023 | N/A | SO ORDERED, re 21 MOTION for Pro Hac Vice Appearance of Attorney Brandon M. White, Emily J. Greb, and Bryan D. Beel, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Ordered by Judge Colm F. Connolly on 5/10/2023. (kmd) (Entered: 05/10/2023) (0) |
| May 10, 2023 | N/A | ORAL ORDER Setting In-Person Scheduling Conference:( A Scheduling Conference is set for 6/6/2023 at 01:30 PM in Courtroom 4B before Judge Colm F. Connolly.) Ordered by Judge Colm F. Connolly on 5/10/2023. (nmf) (Entered: 05/10/2023) (0) |
| May 9, 2023 | 21 | MOTION for Pro Hac Vice Appearance of Attorney Brandon M. White, Emily J. Greb, and Bryan D. Beel - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 05/09/2023) (6) |
| May 8, 2023 | 18 | NOTICE OF SERVICE of (1) Disclosures Under Paragraph 3 of the District of Delaware Default Standard; and (2) Initial Disclosures Pursuant to Fed. R. Civ. P. 26(A) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 05/08/2023) (3) |
| May 8, 2023 | 19 | Joint PROPOSED ORDER -- [Proposed] Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 05/08/2023) (30) |
| May 8, 2023 | 20 | NOTICE OF SERVICE of (1) Defendants Initial Disclosure Under Fed. R. Civ. P. 26(a)(1) and (2) Defendants Disclosures Pursuant to the Delaware Default Standard for Discovery filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 05/08/2023) (2) |
| May 4, 2023 | N/A | SO ORDERED, re 17 STIPULATION TO EXTEND TIME to Submit Proposed Scheduling Order to May 8, 2023, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Setting Deadlines: Notice of Compliance deadline set for 5/8/2023. Ordered by Judge Colm F. Connolly on 5/4/2023. (kmd) (Entered: 05/04/2023) (0) |
| May 3, 2023 | 17 | STIPULATION TO EXTEND TIME to Submit Proposed Scheduling Order to May 8, 2023 - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 05/03/2023) (2) |
| Apr 24, 2023 | 16 | SO ORDERED, re 15 STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order pursuant to the Court's Order (D.I. 10) to May 3, 2023, filed by Novo Nordisk A/S, Novo Nordisk Inc. ReSet Deadlines: Notice of Compliance deadline set for 5/3/2023. Signed by Judge Colm F. Connolly on 4/24/2023. (kmd) (Entered: 04/24/2023) (2) |
| Apr 21, 2023 | 14 | ANSWER to 11 Answer to Complaint, Counterclaim -- Plaintiffs' Answer to Counterclaims -- by Novo Nordisk A/S, Novo Nordisk Inc..(Blumenfeld, Jack) (Entered: 04/21/2023) (16) |
| Apr 21, 2023 | 15 | STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order pursuant to the Court's Order (D.I. 10) to May 3, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Blumenfeld, Jack) (Entered: 04/21/2023) (2) |
| Apr 17, 2023 | N/A | SO ORDERED, re 13 STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order pursuant to the Court's Order (D.I. 10) to April 24, 2023, filed by Novo Nordisk A/S, Novo Nordisk Inc. Resetting Deadlines: Notice of Compliance deadline set for 4/24/2023. Ordered by Judge Colm F. Connolly on 4/17/2023. (kmd) (Entered: 04/17/2023) (0) |
| Apr 14, 2023 | 13 | STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order pursuant to the Court's Order (D.I. 10) to April 24, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Blumenfeld, Jack) (Entered: 04/14/2023) (2) |
| Mar 31, 2023 | 11 | ANSWER to 1 Complaint, , COUNTERCLAIM against All Plaintiffs by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 03/31/2023) (30) |
| Mar 31, 2023 | 12 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Viatris Inc. for Mylan Pharmaceuticals Inc. filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 03/31/2023) (2) |
| Mar 14, 2023 | 10 | ORDER, having been assigned these cases which are listed as related to earlier filed cases that are currently proceeding on an agreed upon schedule entered by the Court; IT IS ORDERED that, on or before April 17, 2023, counsel for the parties shall confer regarding coordination of the cases and submit a proposed scheduling order to the Court or otherwise advise the Court that a separate scheduling conference is needed.ORDER, Setting Deadlines: ( Notice of Compliance deadline set for 4/17/2023.) Signed by Judge Colm F. Connolly on 3/14/2023. Associated Cases: 1:23-cv-00101-CFC, 1:23-cv-00179-CFC(nmf) (Entered: 03/14/2023) (2) |
| Feb 23, 2023 | N/A | Pro Hac Vice Attorney Scott Miller, Joshua Reich, Naz Erdeniz Wehrli, Daniel J. Klein, Peter Sandel, Jenny C. Wu, Josephine Young, and Nicholas P. Groombridge for Novo Nordisk A/S and Novo Nordisk Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 02/23/2023) (0) |
| Feb 21, 2023 | N/A | SO ORDERED, re 9 MOTION for Pro Hac Vice Appearance of Attorney Nicholas P. Groombridge, Josephine Young, Jenny C. Wu, Peter Sandel, Daniel J. Klein, Naz E. Wehrli, Joshua Reich and Scott Mille,r filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 2/21/2023. (kmd) (Entered: 02/21/2023) (0) |
| Feb 17, 2023 | 9 | MOTION for Pro Hac Vice Appearance of Attorney Nicholas P. Groombridge, Josephine Young, Jenny C. Wu, Peter Sandel, Daniel J. Klein, Naz E. Wehrli, Joshua Reich and Scott Miller - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 02/17/2023) (10) |
| Feb 8, 2023 | 8 | WAIVER OF SERVICE returned executed by Novo Nordisk Inc., Novo Nordisk A/S: For Mylan Pharmaceuticals Inc. waiver sent on 1/30/2023, answer due 3/31/2023; Viatris Inc. waiver sent on 1/30/2023, answer due 3/31/2023. (Egan, Brian) (Entered: 02/08/2023) (1) |
| Feb 1, 2023 | N/A | Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) (Entered: 02/01/2023) (0) |
| Feb 1, 2023 | 7 | STANDING ORDER REGARDING BRIEFING IN ALL CASES (nmf) (Entered: 02/01/2023) (2) |
| Jan 27, 2023 | 1 | COMPLAINT FOR ANDA/PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc., Viatris Inc. ( Filing fee $ 402, receipt number ADEDC-4054183.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit 1-5, # 2 Civil Cover Sheet) (vfm) (Entered: 01/27/2023) (Main Document) (30) |
| Jan 27, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 01/27/2023) (3) |
| Jan 27, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/17/2022. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 6/17/2025. (vfm) (Entered: 01/27/2023) (1) |
| Jan 27, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,129,343 B2 ;8,536,122 B2 ;9,764,003 B2 ;10,888,605 B2 ;11,318,191 B2. (vfm) (Entered: 01/27/2023) (1) |
| Jan 27, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo Nordisk US Holdings Inc., Corporate Parent NNAS, Corporate Parent Novo Nordisk Commercial Holdings, Inc. for Novo Nordisk Inc.; Corporate Parent Novo Holdings A/S, Corporate Parent Novo Nordisk Foundation for Novo Nordisk A/S filed by Novo Nordisk A/S, Novo Nordisk Inc.. (vfm) (Entered: 01/27/2023) (2) |
| Jan 27, 2023 | 6 | Summons Issued as to Mylan Pharmaceuticals Inc. on 1/27/2023; Viatris Inc. on 1/27/2023. (Attachments: # 1 Summons Issued) (vfm) (Entered: 01/27/2023) (Main Document) (2) |
| Jan 27, 2023 | N/A | Remark: MDL Panel Notified. (vfm) (Entered: 01/27/2023) (0) |
| Jan 27, 2023 | 1 | COMPLAINT FOR ANDA/PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc., Viatris Inc. ( Filing fee $ 402, receipt number ADEDC-4054183.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit 1-5, # 2 Civil Cover Sheet) (vfm) (Entered: 01/27/2023) (Exhibit 1-5) (30) |
| Jan 27, 2023 | 1 | COMPLAINT FOR ANDA/PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc., Viatris Inc. ( Filing fee $ 402, receipt number ADEDC-4054183.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit 1-5, # 2 Civil Cover Sheet) (vfm) (Entered: 01/27/2023) (Civil Cover Sheet) (2) |
| Jan 27, 2023 | 6 | Summons Issued as to Mylan Pharmaceuticals Inc. on 1/27/2023; Viatris Inc. on 1/27/2023. (Attachments: # 1 Summons Issued) (vfm) (Entered: 01/27/2023) (Summons Issued) (2) |
